Clinical trial
Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG)/Rituximab in Patients…
NCT00278538 · Northwestern University, Other · Completed
Key facts
| NCT number | NCT00278538 |
|---|---|
| Title | Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG)/Rituximab in Patients With Systemic Lupus Erythematosus |
| Official title | Cyclophosphamide and rATG/Rituximab in Patients With Systemic Lupus Erythematosus: Phase II Trial |
| Lead sponsor | Northwestern University, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Systemic Lupus Erythematosus |
| Intervention type | Biological |
| Interventions | Hematopoietic stem cell transplantation |
| Enrollment | 32 |
| Start date | Sep 23, 2005 |
| Primary completion | Dec 1, 2018 |
| Completion | May 1, 2019 |
| First posted | Jan 18, 2006 |
| Last update posted | Feb 28, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: